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Randomised trial for the prevention of delayed emesis in patients
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Summary Despite recent advances in control of acute emesis following cisplatin-based chemotherapy
regimens, delayed emesis remains a significant cause of treatment-related morbidity and factors associated with
delayed emesis have not yet been evaluated. A prospective randomised trial was conducted to compare the
efficacy and toxicity of granisetron, dexamethasone plus prochlorperazine with granisetron alone in controlling
cisplatin-induced delayed emesis and to identify the important factors that influence its occurrence and
severity. Seventy cisplatin-naive patients with inoperable solid tumors participated in the trial. Patients who
received 80 mg m 2 or 100 mg m-2 of cisplatin were randomly assigned to receive either granisetron 40 jg kg-'
intravenously (i.v.) on day 1, dexamethasone 20 mg i.v. on days 2 and 3 and prochlorperazine 5 mg orally
thrice daily on days 1-5 or granisetron 40 fig kg-' i.v. on day I alone. There was no difference in their acute
antiemetic efficacy. A combination regimen was more effective than granisetron alone in preventing delayed
symptoms, with superior rates of complete plus major responses of 77% vs 51% (P = 0.0460). Treatment arm
was the only determinant factor for the occurrence of delayed emesis (P = 0.0101).
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Nausea and vomiting are among the most common and
feared side-effects of cancer chemotherapy. In particular,
cisplatin has been recognised for its high emetogenic poten-
tial (Von Hoff et al., 1979). The quality of life of the cancer
patients and their compliance with treatment, which con-
tinues over several courses, depend on the effective manage-
ment of these side-effects. It is very important to achieve
good control during the first course of chemotherapy in
order to avoid anticipatory nausea and vomiting before the
next or subsequent treatments.
In recent years significant advances in control of acute
emesis during the initial 24 h after cisplatin administration
have been made, using high-dose metoclopramide (Gralla et
al., 1981), dexamethasone (Kris et al., 1983, 1985a) and
5-hydroxytryptamine (5-HT3) antagonists (Cunningham et
al., 1987; Hainsworth and Hesketh, 1992; Jantunen et al.,
1993; Joss et al., 1993). However, the success obtained in the
prevention of acute emesis has not been extended to control
of delayed emesis induced by cisplatin. Delayed emesis
appearing beyond the first 24 h after chemotherapy remains a
significant cause of treatment-related morbidity and patient
refusal of further chemotherapy despite the use of various
antiemetic drugs, including corticosteroids, major tran-
quilisers, and 5-HT3 antagonists. The treatment of choice for
delayed emesis still remains to be established; in fact, only a
few randomised trials have been carried out. The factors
associated with delayed emesis have also not been sufficiently
studied. Therefore, we carried out an open randomised study
to compare the efficacy and safety of a combination of
granisetron, dexamethasone and prochlorperazine with grani-
setron alone in the prophylaxis of delayed emesis, and to
define the factors associated with delayed symptoms induced
by cisplatin in patients who had not previously received
cisplatin-based chemotherapy.
Patients and methods
Patient selection
Eligibility criteria for entry into the study were as follows: (1)
histological diagnosis of malignant tumours: (2) cisplatin
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doses of> 80 mg m2; (3) age<80 years; (4) performance
status of 0, 1 or 2 on the Eastern Cooperative Oncology
Group (ECOG) scale; (5) adequate bone marrow function
(leucocyte countk 4000 il-1, platelet count ) 100 0001-l'
and haemoglobin > 9 g dl-'), adequate hepatic function (bili-
rubin < 1.5 mg dl-', transaminases < twice the upper limit of
normal) and adequate renal function
(creatinine < 1.4 mg dl-', 24 h creatinine clearance
> 60 ml min-1); (6) no presence of nausea and/or vomiting
before the cisplatin treatment; (7) no prior cisplatin-
containing chemotherapy; (8) no current use of cor-
ticosteroids; (9) no new change of doses of major tran-
quilisers or sleeping pills habitually used (prochlorperazine
should not be habitually used); (10) no evidence of severe
uncontrollable diabetes; (11) no evidence of brain metastasis
or brain tumors; (12) no medical problems severe enough to
prevent compliance with the protocol; and (13) written in-
formed consent.
Treatmentprotocol
After eligibility criteria were ascertained, patients were ran-
domly assigned to receive either granisetron alone (arm 1) or
granisetron, dexamethasone, and prochlorperazine (arm 2).
All paitents received- a single high dose of cisplatin
(80 mg m-2 or 100 mgm-2) for the first time in combination
with other chemotherapeutic agents consisting of 6-9
mgm-2 of vindesine, 8 mgm-2 of mitomycin C, or
300 mg m-2 of etoposide. They also received 40 Ig kg-' of
granisetron intravenously (i.v.) 15 min before cisplatin
administration was given as a single i.v. infusion on day 1.
Patients assigned to treatment arm 1 received no preventive
antiemetics except granisetron on day 1, and patients
allocated to treatment arm 2 received 20mg of dex-
amethasone i.v. on days 2 and 3, and 5 mg tablets of pro-
chlorperazine orally three times (30 min before breakfast,
lunch and dinner) on days 1-5. If more than two episodes of
severe nausea or vomiting were observed, patients received a
standard dose (10 mg per body i.v. or intramuscularly; i.m.)
of metoclopramide.
Definition ofresponse
Following the cisplatin administration, each patient was
monitored by direct observation, patient interviews and bed-
side self-assessment. An emetic episode was defined as either
an episode of vomiting or retching. We attempted to assessControl of delayed emesis induced by cisplatn
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other parameters including nausea and appetite loss. The
primary efficacy parameter was the number of emetic
episodes. Nausea and food intake assessment were used as
secondary parameters in evaluating the efficacy. The number
of episodes of vomiting and severity of nausea was recorded
during each 24 h period for 5 days after cisplatin administra-
tion. Each patient was asked to count the number of emetic
episodes during each interval. The duration and severity of
nausea were rated by patients, for the same intervals, on
categorical descriptive scales that were divided into two
grades. The baseline assessment of food intake was obtained
immediately before cisplatin administration. The level of
appetite was checked at each meal for 5 days. The categories
on scales of emetic episodes, nausea and appetite loss are as
follows. Responses for vomiting and retching are graded as
complete control (no emetic episodes), grade 0; major control
(1-2 emetic episodes), grade 1; failure ( > three emetic
episodes), grade 2. Responses for nausea were also recorded
according to two graded scales by patients as no or mild
nausea, good control; moderate or severe nausea, failure.
Food intake was assessed by four graded scales as being: as
usual, grade 0; half of the usual, grade 1; one-third of the
usual, grade 2; less than one-third of the usual, grade 3. They
were recorded every day on days 2-5 and the worst day
analysis was performed. The criteria of the worst day
analysis for delayed emesis were as follows: complete control,
the absence of nausea, vomiting and retching; major control,
grade 1 emetic episodes or grade 0 emetic episode with mild
nausea; and others were classified as failure.
Evaluationfor toxicities
Toxicities were classified using World Health Organization
criteria (World Health Organization, 1979). Other adverse
effects, which have no grading in the WHO criteria, were
classified as follows: grade 0, no symptom; grade 1, mild;
grade 2, moderate; grade 3, severe; grade 4, extremely severe
and/or life-threatening.
Statistical analysis
Analyses of nausea and emetic episodes were performed
separately for day 1 (acute emesis) and days 2-5 (delayed
emesis).
This trial was planned to include 62 patients to provide of
more than 80% power to detect at the 5% level a 30%
increase in overall control of delayed emesis from the
anticipated 50% in the granisetron alone group.
Chi-square test or Fisher's exact test was used to compare
response rates of the worst day analysis as well as to evaluate
the imbalance of factors between the two groups. The statis-
tical significance of differences in the distribution of the age
was determined using paired, two-tailed Student's t-test. The
Mann-Whitney U-test was used to compare daily grades of
emetic episodes and nausea between two treatment groups.
Multivariate analysis ofprognostic variables for response was
carried out using a logistic regression model. All P-values
refer to a two-sided significance test, and a P-value of less
than 0.05 was considered to be statistically significant.
Results
Patient characteristics
Between April 1993 and January 1995, a total of 70 patients
were entered into the study and all were eligible. Sixty-eight
patients had lung cancer and two had colon cancer with lung
metastases. Both groups of patients (granisetron alone vs
granisetron, dexamethasone plus prochlorperazine) were well
matched for age, sex, performance status and daily alcohol
consumption (75 g or more) (Table I).
Acute nausea
Patterns and the severity of acute nausea between the two
groups did not differ. The rates of no or mild nausea
observed during the first 24 h were 69% in a combination of
granisetron, dexamethasone and prochlorperazine, and 54%
in a granisetron-alone group (P = 0.3267).
Acute emetic episodes
The rates of complete emetic control were 51% in arm 1 and
66% in the 2 (P = 0.3318). The rates of complete plus major
emetic control were similar, with 72% in treatment arm 1 vs
77% in treatment arm 2 on day 1 (P = 0.7845). A variety of
factors were analysed to determine their impact on the cont-
rol of acute emesis. Gender and a habitual high alcohol
intake ( > 75 g per day) were significant for controlling acute
emesis and P-values were 0.0043 and 0.0161 respectively. A
multivariate analysis showed that gender was the only
significant factor for control of acute emesis among six fac-
tors (P = 0.0044).
Delayed nausea
The rates of no or mild nausea were 43% in arm 1 and 74%
in arm 2 on day 2 (P = 0.0153), and on day 3, 54% in arm 1
and 72% in arm 2 (P = 0.2162). Three patients only
experienced most severe nausea after day 3.
Table I Patients characteristics
Arm I Arm 2 P-value
No. of patients 35 35
Gender: Male/Female 26/9 28/7 0.7759
Median age (range) 63 (37-75) 63 (41-75) 0.8412
Histological type
Lung cancer
NSCLC 29 27
SCLC 4 8 0.1842
Colon cancer 2 0
Performance status (ECOG)
0, 1/2 22/13 25/10 0.6103
Chest irradiation: Yes/No 5/30 11/24 0.1547
Habitual alcohol intake
High/Low 8/27 5/30 0.5387
Chemotherapeutic regimen
PV 9 12
MVP 22 17 0.4796
PE 4 6
NSCLC, non-small-cell lung carcinoma; SCLC, small-cell lung carcinoma; PV,
cisplatin 100 mg m-2 + vindesine 3 mgm-2; MVP, cisplatin 80 mg m-2 + mitomycin
8mgm-2 + vindesine 3mgm-2; PE, cisplatin 80mgm-2 + etoposide 100 mgm-2
x 3 days. Habitual high alcohol intake, >75 g daily.Control of delayed emesis induced bycisplatin
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Delayed emetic episodes
The rates of complete plus major control were 63% in treat-
ment arm 1 and 86% in arm 2 on day 2 (P = 0.0450). Almost
all of the patients experienced the worst vomiting episodes on
day 2 or day 3 in both of the treatment arms, and then the
number of emetic episodes declined.
Duration ofnausea and vomiting
Eighteen (51%) patients experienced nausea for 4 or more
days on arm 1 and nine (26%) on the 2 arm and four (11%)
and five (14%) patients experienced 4 or more days of emetic
episodes respectively.
Worst day analysisfor delayed emesis
Complete plus major control rates for delayed emesis were
51% (95% confidence interval, 34-69%) in the granisetron
alone group and 77% (95% confidence interval, 60-90%) in
the combination therapy group; the difference was statis-
tically significant (P = 0.0460). Nine potential factors for the
control of delayed emesis were analysed in univariate analysis
(Table II). Presence of prior non-cisplatin chemotherapy,
simultaneous chest irradiation, and performance status were
not important factors determining the incidence of emetic
episodes. Gender was also not a significant factor on an
overall control rate, but significant for complete control
(P = 0.0077). A habitual high alcohol intake and good cont-
rol of acute emesis were significant factors, indicating a good
protection from delayed emesis. In this trial, all habitual high
alcohol users were men. When patients were divided into the
three groups of women, men without a habitual high alcohol
intake and men with a habitual high alcohol intake, the
control rates were 50%, 61% and 92% respectively
(P = 0.0482).
Multivariate logistic regression analysis of variables, in-
cluding age, performance status, gender, concurrent chest
irradiation, presence of non-cisplatin containing prior ther-
apy, level of acute emesis and habitual alcohol intake for
protection from delayed emesis was carried out (Table III).
Treatment arm (P = 0.0101) was only of independent prog-
nostic significance for attaining a major control of delayed
emetic episodes.
Safety
There were no differences in toxicity during the trial between
the two arms. Headache is known to be the most common
adverse event in patients receiving 5-HT3-blockers. In our
study, five patients (7%) experienced grade 1 headache, but
needed no treatment. Six patients (9%) experienced constipa-
tion on day 1. Dexamethasone plus prochlorperazine for
control of delayed emesis was extremely well tolerated by
Table II Response rate for delayed emisis according to prognostic factor
No. of Complete Major Response
patients control controt % P-value
Arm
1 35 7 11 18 (51) 0.0460 2 35 10 17 27 (77)
Gender
Male 54 17* 20 37 (69) 02888
Female 16 0* 8 8 (50)
Age (years)
>,64 32 10 13 12 (92) 03342
<64 38 7 15 33 (58)
PS (ECOG)
0, 1 47 12 17 29 (62) 07044
2 23 5 11 16 (70)
Habitual alcohol intake
>75g daily 13 10** 2 12 (92) 00242
<75 gdaily 57 7** 26 33 (58)
Prior therapy
Yes 29 5 12 17 (59) 0.5628 No 41 12 16 28 (68)
CDDP dose (mgm-2)
80 49 10 20 30 (61) 05862
100 21 7 8 15 (71)
Chest irradiation
Yes 16 5 5 10 (63) 0.6604
No 54 12 23 35 (65)
Response for acute emisis
Responder 52 16 22 38 (73) 00201
Non-responder 18 1 6 7 (39)
aComplete control (experienced no nausea and no emetic episode). bMajor control
(experienced 0 emetic episode with any nausea or 1-2 emetic episodes), *P=0.0077;
**P<0.0001.
Table III Multivariate analysis of variables for delayed emesis
Parameters Odds ratio 95% Confidence Interval P-value
Arm 0.2065 0.0576 0.6555 0.0101
Habitual high alcohol intake 0.1130 0.0053 0.8287 0.0668
Control of actue emesis 2.7548 0.6973 11.7835 0.1536
Chest irradiation 0.3859 0.0694 1.9029 0.2495
Dose of CDDP 2.3404 0.4725 13.6819 0.3124
Age 1.3813 0.4080 4.7214 0.5998
Prior therapy 1.4051 0.3622 5.7327 0.6248
Performance status 1.2026 0.3366 4.4046 0.7752
Gender 0.8326 0.1817 3.8903 0.8120
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patients, and no major drug-related adverse effects (more
than grade 1) were observed. No patient experienced dystonic
reactions, somnolence, extrapyramidal symptom and seda-
tion. Two patients (3%) experienced grade 1 face rush. These
adverse effects were mild, transient and easily tolerable.
Discwi
The 5-HT3 antagonists have improved the treatment of acute
cisplatin-induced nausea and vomiting. Chevallier (1993)
reported the trial comparing granisetron alone with high-dose
metoclopramide plus dexamethasone, showing that no
significant differences were detected between the two groups
in the incidence of acute emesis induced by cisplatin. The
incidence of delayed emesis induced by cisplatin was reported
to be 50-70% when 5-HT3 antagonists were used to control
acute emesis (Gandara et al., 1992; Italian Group for
Antiemetic Research, 1993; Kaizer et al., 1994). In contrast
to the success in the protection from acute emesis, the 5-HT3
antagonists seem to be less effective against delayed emetic
symptoms (Kaye et al., 1992). Several antiemetics including
dexamethasone, minor tranquilisers and selective dopamine
D2 antagonists, which may have different mechanisms of
actions, have been reported effective in the control ofdelayed
emesis (Hamik and Peroutka, 1989; Kris et al., 1989; Louvet
et al., 1991; Moreno et al., 1992; Herrstedt et al., 1993).
Dexamethasone has improved the antiemetic effect of a 5-
HT3 antagonist in patients receiving cisplatin-based chemo-
therapy. Combined use of these agents seems more effective
in the control of delayed emesis than any single drug alone.
Based on these data, this randomised study compared the
three-drug combination of a 5-HT3 antagonist gramisetron,
dexamethasone and prochlorperazone with the treatment
with granisetron alone in the prevention of delayed nausea
and vomiting in patients receiving cisplatin-containing
regimens, demonstrating the apparent advantage for overall
control of delayed emesis of combination therapy over
granisetron alone (77% in the combination group vs 51% in
the granisetron alone; P= 0.0460) (Table II). There was a
statistically significant 26% difference in the complete and
major control rates between the two arms.
In agreement with other investigators (Kris et al., 1985b,
1989; Gandara et al., 1992), the highest incidence of delayed
emesis was observed on day 2 after cisplatin administration,
and only three patients experienced first delayed emesis on
day 4 or later in our study. Delayed emesis seems to become
a smaller problem if it is well controlled on days 2 and 3.
Therefore, every effort should be directed to obtaining
perfect protection from both acute and delayed emesis on
days I -3.
Dose of cisplatin, control of acute emesis and gender have
previously been reported as important determinants for
delayed emesis (Kris et al., 1985a; Roila et al., 1991; Italian
Group for Antiemetic Research 1994). In this study, dose of
cisplatin (80 mg m-2 or 100 mgmn-) was also not a
significant factor. This may be because all patients received
high-dose cisplatin (either dose level of 80 mg m-2 or
100 mg m-2) (Table II). Treatment arm, habitual high
alcohol intake and control of acute emesis were significant
variables in univariate analysis. Multivariate analysis using
logistic regression models revealed that treatment arm (arm 1
or arm 2) was the only important factor (P = 0.0101) (Table
III). A habitual high alcohol intake was the second, but did
not reach statistical significance. The importance of complete
control of acute emesis, which is often quoted as a significant
determinant of subsequent antiemetic control, was not
confirmed by multivariate analysis. This may be explained by
different characteristics of population in this study, or by the
relatively small number of patients, which provides only a
low statistical power for detecting differences of moderate
magnitude between the groups.
In conclusion, a combination of granisetron, dex-
amethasone and prochlorperazine was more effective than
granisetron alone in protection from delayed emesis after
high-dose cisplatin. Since 23% of patients treated with the
combination regimen suffered from severe delayed emesis,
further studies with other more effective combinations of
antiemetics with different mechanisms of action are needed to
improve results in this population.
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